PT - JOURNAL ARTICLE AU - Wahid, Kareem A. AU - Sahin, Onur AU - Kundu, Suprateek AU - Lin, Diana AU - Alanis, Anthony AU - Tehami, Salik AU - Kamel, Serageldin AU - Duke, Simon AU - Sherer, Michael V. AU - Rasmussen, Mathis AU - Korreman, Stine AU - Fuentes, David AU - Cislo, Michael AU - Nelms, Benjamin E. AU - Christodouleas, John P. AU - Murphy, James D. AU - Mohamed, Abdallah S. R. AU - He, Renjie AU - Naser, Mohammed A. AU - Gillespie, Erin F. AU - Fuller, Clifton D. TI - Determining The Role Of Radiation Oncologist Demographic Factors On Segmentation Quality: Insights From A Crowd-Sourced Challenge Using Bayesian Estimation AID - 10.1101/2023.08.30.23294786 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.30.23294786 4099 - http://medrxiv.org/content/early/2023/09/05/2023.08.30.23294786.short 4100 - http://medrxiv.org/content/early/2023/09/05/2023.08.30.23294786.full AB - BACKGROUND Medical image auto-segmentation is poised to revolutionize radiotherapy workflows. The quality of auto-segmentation training data, primarily derived from clinician observers, is of utmost importance. However, the factors influencing the quality of these clinician-derived segmentations have yet to be fully understood or quantified. Therefore, the purpose of this study was to determine the role of common observer demographic variables on quantitative segmentation performance.METHODS Organ at risk (OAR) and tumor volume segmentations provided by radiation oncologist observers from the Contouring Collaborative for Consensus in Radiation Oncology public dataset were utilized for this study. Segmentations were derived from five separate disease sites comprised of one patient case each: breast, sarcoma, head and neck (H&N), gynecologic (GYN), and gastrointestinal (GI). Segmentation quality was determined on a structure-by-structure basis by comparing the observer segmentations with an expert-derived consensus gold standard primarily using the Dice Similarity Coefficient (DSC); surface DSC was investigated as a secondary metric. Metrics were stratified into binary groups based on previously established structure-specific expert-derived interobserver variability (IOV) cutoffs. Generalized linear mixed-effects models using Markov chain Monte Carlo Bayesian estimation were used to investigate the association between demographic variables and the binarized segmentation quality for each disease site separately. Variables with a highest density interval excluding zero — loosely analogous to frequentist significance — were considered to substantially impact the outcome measure.RESULTS After filtering by practicing radiation oncologists, 574, 110, 452, 112, and 48 structure observations remained for the breast, sarcoma, H&N, GYN, and GI cases, respectively. The median percentage of observations that crossed the expert DSC IOV cutoff when stratified by structure type was 55% and 31% for OARs and tumor volumes, respectively. Bayesian regression analysis revealed tumor category had a substantial negative impact on binarized DSC for the breast (coefficient mean ± standard deviation: –0.97 ± 0.20), sarcoma (–1.04 ± 0.54), H&N (–1.00 ± 0.24), and GI (–2.95 ± 0.98) cases. There were no clear recurring relationships between segmentation quality and demographic variables across the cases, with most variables demonstrating large standard deviations and wide highest density intervals.CONCLUSION Our study highlights substantial uncertainty surrounding conventionally presumed factors influencing segmentation quality. Future studies should investigate additional demographic variables, more patients and imaging modalities, and alternative metrics of segmentation acceptability.Competing Interest StatementCDF has received travel, speaker honoraria and/or registration fee waiver unrelated to this project from: The American Association for Physicists in Medicine; the University of Alabama-Birmingham; The American Society for Clinical Oncology; The Royal Australian and New Zealand College of Radiologists; The American Society for Radiation Oncology; The Radiological Society of North America; and The European Society for Radiation Oncology.Funding StatementKAW was supported by an Image Guided Cancer Therapy (IGCT) T32 Training Program Fellowship from T32CA261856. CDF received/receives unrelated funding and salary support from: NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic Industrial Partnership Grant (R01DE028290) and the Administrative Supplement to Support Collaborations to Improve AIML-Readiness of NIH-Supported Data (R01DE028290-04S2); NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions award (R01DE025248); NSF/NIH Interagency Smart and Connected Health (SCH) Program (R01CA257814); NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787); NIH NIDCR Exploratory/Developmental Research Grant Program (R21DE031082); NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); Patient-Centered Outcomes Research Institute (PCS-1609-36195) sub-award from Princess Margaret Hospital; National Science Foundation (NSF) Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369). CDF receives grant and infrastructure support from MD Anderson Cancer Center via: the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program; the Program in Image-guided Cancer Therapy; and the NIH/NCI Cancer Center Support Grant (CCSG) Radiation Oncology and Cancer Imaging Program (P30CA016672).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All C3RO data, including the original demographic factors and segmentation data are available on Figshare (DOI = doi.org/10.6084/m9.figshare.21074182).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesCorresponding newly created data and spreadsheets generated for this study can also be found on Figshare (DOI = doi.org/10.6084/m9.figshare.24021591).